FDA Approves Lazanda® – First Fentanyl Nasal Spray – for the Management of Breakthrough Pain in Cancer Patients
Drug Abuse Methadone: FDA Approves Lazanda® – First Fentanyl Nasal Spray – for the Management of Breakthrough Pain in Cancer Patients
READING, England and BEDMINSTER, N.J., June 30, 2011 /PRNewswire/ — Archimedes Pharma Ltd., and its subsidiary, Archimedes Pharma U.S. Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Lazanda® (fentanyl) nasal spray for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid …
Drug Abuse Methadone – Yahoo! News Search Results
Find More Drug Abuse Methadone Information…